DBV Technologies (NASDAQ:DBVT) Shares Down 6.9% – What’s Next?

DBV Technologies S.A. (NASDAQ:DBVT) shares dropped 6.9% during mid-day trading on Wednesday . The company traded as low as $16.30 and last traded at $16.15. Approximately 49,508 shares traded hands during trading, a decline of 83% from the average daily volume of 296,577 shares. The stock had previously closed at $17.35.

Analyst Ratings Changes

Several research firms have recently weighed in on DBVT. Weiss Ratings reiterated a “sell (d-)” rating on shares of DBV Technologies in a research report on Monday, June 29th. Citigroup reissued an “outperform” rating on shares of DBV Technologies in a research report on Friday, May 1st. HC Wainwright restated a “buy” rating on shares of DBV Technologies in a research note on Tuesday, June 30th. Citizens Jmp lifted their price target on shares of DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a research note on Tuesday, June 30th. Finally, Guggenheim restated a “buy” rating and set a $51.00 price objective on shares of DBV Technologies in a report on Monday, May 4th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $48.50.

DBV Technologies Price Performance

The company has a market cap of $993.58 million, a PE ratio of -3.76 and a beta of -0.95. The business has a fifty day simple moving average of $17.84 and a two-hundred day simple moving average of $19.72.

DBV Technologies (NASDAQ:DBVT) last released its quarterly earnings results on Thursday, April 30th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.42). The company had revenue of $0.90 million during the quarter, compared to the consensus estimate of $1.11 million. DBV Technologies had a negative return on equity of 129.88% and a negative net margin of 2,895.37%. On average, equities research analysts predict that DBV Technologies S.A. will post -0.38 EPS for the current year.

Hedge Funds Weigh In On DBV Technologies

Several institutional investors and hedge funds have recently bought and sold shares of DBVT. MPM Bioimpact LLC purchased a new stake in shares of DBV Technologies during the 2nd quarter valued at $9,649,000. Adage Capital Partners GP L.L.C. acquired a new position in DBV Technologies during the 2nd quarter valued at about $9,659,000. Octagon Capital Advisors LP acquired a new position in DBV Technologies during the 2nd quarter valued at about $9,315,000. Two Sigma Investments LP purchased a new stake in DBV Technologies in the third quarter valued at about $167,000. Finally, Citadel Advisors LLC acquired a new stake in DBV Technologies in the third quarter worth about $220,000. 71.74% of the stock is owned by hedge funds and other institutional investors.

About DBV Technologies

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.